中国批准第一款国产核糖核酸型新冠疫苗

中国批准第一款国产核糖核酸型新冠疫苗

A new report reveals that messenger RNA (mRNA) technology, used in COVID-19 vaccines, is important in the fight against the Omicron variant. The study found that the Moderna and BioNTech mRNA vaccines still maintained an 85.3% efficacy rate against Omicron after the addition of a third dose. The report also supports the development of mRNA vaccines for future variants.

Key takeaways from the meeting notes:
– mRNA technology is being used in COVID-19 vaccines from Moderna and BioNTech.
– The Omicron variant has multiple sub-lineages, including BA.5, BF.7, BQ.1.1., XBB.1.5, and CH.1.1.
– The Pfizer-BioNTech vaccine has shown 85.3% effectiveness against the Omicron variant.
– The mRNA technology has the potential to be used for other diseases in the future.
– David Heymann, an expert in infectious diseases, believes that mRNA technology has great potential for future vaccine development.

新闻原文链接 https://www.rfi.fr/cn/%E4%B8%AD%E5%9B%BD/20230323-%E4%B8%AD%E5%9B%BD%E6%89%B9%E5%87%86%E7%AC%AC%E4%B8%80%E6%AC%BE%E5%9B%BD%E4%BA%A7%E6%A0%B8%E7%B3%96%E6%A0%B8%E9%85%B8%E5%9E%8B%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97